Search

Veracyte Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

41.21 -3.04

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

40.98

Max

43.6

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-3.2M

25M

Pardavimai

11M

150M

P/E

Sektoriaus vid.

33.774

57.002

Pelnas, tenkantis vienai akcijai

0.37

Pelno marža

16.957

Darbuotojai

755

EBITDA

-11M

24M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+35.56% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-718M

3.7B

Ankstesnė atidarymo kaina

44.25

Ankstesnė uždarymo kaina

41.21

Naujienos nuotaikos

By Acuity

50%

50%

171 / 340 reitingas Healthcare

Veracyte Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-13 19:51; UTC

Veracyte Inc shares are lower today, breaking a trend of higher closes. No specific news was identified for this decline amid notable market volume.

2026-08-12 20:01; UTC

Veracyte Inc shares are lower today, following a broader market decline. The stock remains significantly below its 20-day moving average.

2026-08-11 19:26; UTC

News

Veracyte Inc reported second-quarter revenue of $150.32 million and raised its 2026 outlook to $590 million to $596 million, boosting shares higher.

2026-08-10 19:36; UTC

News

Veracyte Inc shares declined Monday, trading lower since Friday's close amid broader market volatility and rising oil prices affecting inflation expectations.

2026-08-07 19:26; UTC

Correlated Moves

Veracyte Inc shares are higher, supported by a rise in the ARK Genomic Revolution ETF and broader small-cap strength from the Russell 2000 Index.

2026-08-06 19:26; UTC

Veracyte Inc shares are higher today, despite earlier losses. No specific news was identified to explain the price movement during the session.

2026-08-05 19:32; UTC

Veracyte Inc's shares are lower, reflecting broader market sentiment amid recent crude oil price declines. Trading volume is unusually high today.

2026-08-04 19:36; UTC

News
Correlated Moves

Veracyte shares are rising as Piper Sandler and Stephens maintain Overweight ratings, despite lowering price targets to $54 and $55, respectively.

2026-08-03 20:06; UTC

Veracyte Inc's shares are lower today, diverging from broader market gains amid high trading volume. No specific news was identified to explain the decline.

2026-08-01 00:01; UTC

Veracyte Inc is trading lower in after-market hours, reflecting broader market declines. Shares remain near the lower end of their one-month range.

2026-07-31 20:02; UTC

News
Social Media

Veracyte Inc shares are lower despite positive analyst outlooks and target increases from Freedom and Needham following a recent earnings report that exceeded expectations.

2026-07-30 23:21; UTC

News
Social Media

Veracyte shares fell in after-market trading despite reporting second-quarter revenue of $150.3 million and adjusted EPS of $0.54, exceeding expectations.

2026-07-29 19:47; UTC

Macro Event

Veracyte Inc's shares are advancing as the Federal Reserve maintains interest rates. The decision aligns with market expectations amid ongoing economic expansion.

2026-07-28 15:22; UTC

Veracyte Inc. shares are higher today, supported by broader strength in biotechnology stocks. No specific news was identified to explain the price movement.

2026-07-27 20:14; UTC

Veracyte Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment may be affected by declining crude oil prices.

2026-07-24 22:16; UTC

Correlated Moves

Veracyte Inc shares declined during after-market hours, reflecting broader weakness in the biotechnology sector. The stock shifted toward the lower end of its one-month trading range.

2026-07-22 20:13; UTC

Correlated Moves

Veracyte Inc shares are lower in after-market trading, reflecting broader market declines amid rising crude oil prices and geopolitical tensions.

2026-07-21 17:16; UTC

Correlated Moves

Veracyte Inc shares are higher today, recovering after three days of declines. The stock is now above its 20-day moving average.

2026-07-20 20:01; UTC

Correlated Moves

Veracyte Inc shares declined sharply today, marking three consecutive lower sessions amid broader market weakness and heightened volatility related to geopolitical tensions.

Akcijų palyginimas

Kainos pokytis

Veracyte Inc Prognozė

Kainos tikslas

By TipRanks

35.56% į viršų

12 mėnesių prognozė

Vidutinis 57.75 USD  35.56%

Aukščiausias 70 USD

Žemiausias 44 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Veracyte Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

8

Pirkti

1

Laikyti

1

Parduoti

Rinkos nuotaikos

By Acuity

171 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
help-icon Live chat